Back to Top Skip to main content

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency, U.S. Armed Forces, May 2004–September 2018

Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt) Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt)

Recommended Content:

Medical Surveillance Monthly Report

ABSTRACT

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder most commonly associated with hemolytic anemia. Among those with G6PD deficiency, hemolytic anemia may be triggered by bacterial or viral infections and by certain foods and drugs, including the 8-aminoquinoline (8-AQ) class of antimalarials. Because 8-AQ drugs remain the only drugs approved by the U.S. Food and Drug Administration for malaria relapse prevention, the Department of Defense (DoD) requires testing of all service members’ G6PD status. To estimate prevalence of G6PD deficiency among DoD service members, Composite Health Care System-generated, Health Level 7-formatted laboratory records for all service members (n=2,311,223) dated between May 2004 and September 2018 were queried for G6PD testing. Corresponding demographic data were obtained from the Defense Enrollment Eligibility Reporting System. Overall prevalence of G6PD deficiency among this cohort was low, at 2.2%. Demographic trends mirrored U.S. statistics; the cohort prevalence among males (2.3%) was higher than among females (1.5%), and the prevalence among non-Hispanic blacks (9.5%) was higher than among those in any other race/ethnicity group.

WHAT ARE THE NEW FINDINGS?    

Test results for 2,311,223 active duty service members over a 14-year period confirmed previous service-specific surveillance reports about the prevalence of G6PD deficiency. The deficiency was found in 2.2% of all service members, and the prevalence ranged from 11.2% among non-Hispanic black males to 0.3% among non-Hispanic white females. To the authors’ knowledge, this is the first DoD report widely addressing the prevalence of G6PD deficiency among active duty service members.

WHAT IS THE IMPACT ON READINESS AND FORCE HEALTH PROTECTION?

Service members who travel or deploy to malaria-endemic regions are at risk of malaria infection. Because of the risk of hemolytic anemia from use of the 8-AQ class of antimalarial drugs (e.g., primaquine, tafenoquine), military leaders should be aware of G6PD deficiency diagnoses among service members under their purview and should continue adherence to current DoD G6PD screening policies.

BACKGROUND

Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme for the pentose phosphate pathway in the erythrocyte because it converts glucose-6-phosphate to 6-phosphoglucono-d-lactone. G6PD also converts nicotinamide adenine dinucleotide phosphate (NADP) to the reduced form of NADP (NADPH), a critical redox-active cofactor that mitigates oxidative damage to the erythrocytes.G6PD deficiency is a genetic condition arising from mutations on the Gd gene on the X chromosome that encodes G6PD enzyme. As an X-linked recessive genetic disorder, G6PD deficiency has a higher prevalence in males than females.1 Reduced G6PD activity in G6PD deficient individuals can cause hemolysis with different manifestations (e.g., kernicterus in infants and hemolytic crises) from exposures to oxidative stressors including certain medications, fava beans, and infections.1,2 For example, members of the 8-aminoquinoline (8-AQ) class of antimalarial drugs can cause hemolysis in the G6PD deficient population. 

8-AQ class antimalarial drugs (primaquine and the newly Food and Drug Administration (FDA)-approved tafenoquine for weekly chemoprophylaxis and single-dose radical cure) are important because they target hypnozoites—a dormant form of the malaria parasite common in Plasmodium vivax and P. ovale infections that can emerge from the liver and cause relapse days to years after treatment has cleared the malaria parasites from the circulating red blood cells. Although these infections are less often fatal than P. falciparum infections, they still can cause significant morbidity because of relapse from the dormant form of the parasites. Because the 8-AQ class drugs are the only FDA-approved drugs for malaria relapse prevention, the Department of Defense (DoD) mandated G6PD testing of service members at the time of military accession as early as 1981 (Instruction 6465.13,4 updated with DoD Instruction 6465.015 in 2015 and 6025.146 in 2018), and the Army implemented additional G6PD screening of soldiers deploying to malaria endemic regions as early as 2004.7 However, given that this drug class may trigger hemolytic anemia among those who are G6PD deficient, it is important to adhere to DoD G6PD screening instructions and provide results to command leaders and tested individuals for situational awareness and force protection.

Thus, the objectives of this surveillance report are to describe the prevalence of G6PD deficiency among active duty DoD service members who were screened during 2004–2018 and remind the DoD medical community to consider the risk of hemolytic anemia when prescribing the use of the 8-AQ class of antimalarial drugs.

METHODS

This cross-sectional study used Composite Health Care System-generated, Health Level 7-formatted chemistry laboratory records from 01 May 2004 through 30 September 2018 and queried for G6PD laboratory test results among all active duty, recruit, and active reserve DoD service members tested at fixed military treatment facilities (MTFs). Generally, G6PD testing occurs during accession (recruit training), which is reflected in over 90% of these records.

Key terms used to identify G6PD assays were “G6” or “glucose 6” in the test ordered or test name fields. G6PD tests are often run in panels with other genetic and hemoglobin tests. Records were excluded from the analysis if the test name field contained text indicating other genetic testing (e.g., “sickle cell anemia”), “red blood count,” “hemoglobin testing,” “miscellaneous,” or if the test type could not be determined.

G6PD laboratory test result fields were alpha character–based or numeric. Character-based records with a test result of “Not Deficient,” “High,” or “Normal” were classified as “Not Deficient.” Records with a test result of “Deficient” or “Low” were classified as “Deficient.” Because of laboratory testing variations between MTFs, numeric test results were classified based upon the reference ranges indicated in the record. If a record had no reference range but units of measure were noted, the reference range was inferred based on other tests with the same unit of measure. In an effort to provide an accurate denominator, if the test result was numeric and the units of measure and the reference ranges could not be extrapolated from the data, the record result was classified as “Unknown.” To avoid misclassification of results, if the test result field referred to the free-text result notes field, the record was classified as “Unknown.”

If a service member had more than 1 record and the test results differed, the records were prioritized as follows: a “Deficient” record was retained over a “Not Deficient” or “Unknown” record, and a “Not Deficient” record was retained over an “Unknown” record. Only 1 record per service member was retained for analysis.

Final records were matched to the most recent Defense Enrollment Eligibility Reporting System (DEERS) record for each service member to obtain race/ethnicity and service affiliation. Records were not included in the final dataset if there were no matching DEERS records (n=29,642). Demographic frequencies and distributions for the final cohort were calculated using SAS software, version 9.4 (SAS Institute, Cary, NC).

RESULTS

Overall results are presented in Table 1. G6PD laboratory test results for 2,311,223 service members were evaluated. Examination of laboratory records indicated that the vast majority (97.7%) of service members tested were not G6PD deficient. Only 0.13% of all records could not be classified. The majority of service members represented in this analysis (89.5%) had 1 record for G6PD testing, 8.7% had 2 records, and the remaining 1.8% had 3 or more records (data not shown). Of those with more than 1 record where the classification changed, the following changes were observed: “Not Deficient” to “Deficient” (4.6%), “Unknown” to “Deficient” (3.7%), and “Unknown” to “Not Deficient” (91.7%) (data not shown).

Of the 2,311,223 service members identified in the laboratory records as having been tested, 83.3% were male and 16.7% were female. Sex was not indicated in 3,070 records (0.13%). Males were more likely to be classified as G6PD deficient (2.3%) than females (1.5%).

Race/ethnicity was classified as “other/unknown” in 3.0% of all records (Table 1). Non-Hispanic blacks were most likely to be classified as G6PD deficient (9.5%), followed by Asians/Pacific Islanders (2.9%) and Hispanics (1.5%). Non-Hispanic whites were the least likely to be classified as G6PD deficient (0.4%).

The G6PD classifications stratified by race/ethnicity and sex are shown in Table 2. Among males, non-Hispanic black service members were the most likely to be classified as G6PD deficient (11.2%), followed by Asian/Pacific Islander and Hispanic service members (3.3% and 1.7%, respectively). Non-Hispanic black males were more than twice as likely as non-Hispanic black females (4.7%) to be classified as G6PD deficient. Non-Hispanic black females had the highest proportion of G6PD deficiency of all female race/ethnicity groups. Although the non-Hispanic white race/ethnicity group represented the largest proportion of service members tested (59.8%), males and females in this race/ethnicity group were least likely to be G6PD deficient (0.4% and 0.3%, respectively).

Table 3 illustrates the G6PD results by service. The proportions of service members who tested positive for G6PD deficiency were broadly similar among the services. The Army had the highest percentage of service members with G6PD deficiency (2.7%), followed by the Air Force (2.3%) and Navy (2.2%). The Coast Guard (1.2%) and the Marine Corps (1.1%) had the lowest rates of service members with G6PD deficiency.

EDITORIAL COMMENT

The current study found an overall G6PD deficiency prevalence rate of 2.2% (n=49,897) among the 2,311,223 active and reserve component service members with laboratory results. To the authors’ knowledge, this is the largest study of G6PD deficiency screening among DoD service members. The results of the current analysis are consistent with other studies that have found that non-Hispanic black males are more likely to be G6PD deficient than any other race/ethnicity group.7–10

Before adoption of the newly FDA-approved tafenoquine as the primary force health protection measure for DoD service members against malaria infection, it is critical to understand the indications for prevention and treatment as well as the limitations.11 Regardless of an improved drug performance, including a radical curative efficacy, longer drug half-life, and once-weekly dosing regimen, tafenoquine still retains the risk of inducing hemolytic anemia in G6PD deficient individuals.

The results of this study must be interpreted within the context of several limitations. Laboratory records queried for this analysis were derived from fixed MTFs and do not include records from in-theater, shipboard, battalion aid station, or Purchased CareThe TRICARE Health Program is often referred to as purchased care. It is the services we “purchase” through the managed care support contracts.purchased care providers, although inclusion of these records, were they available, would not be expected to alter the findings presented herein. Genetic testing is generally performed during the accession phase of military service, so very few tests would need to be performed at austere or remote locations. Although validation steps were taken to avoid misclassification, it is possible that some results were misclassified. Because less than 1.0% of all records were classified as “Unknown,” it is unlikely that these results would change the overall prevalence rates. Final laboratory records were matched to the most recent DEERS record for each service member; a service member may have changed service affiliation after the laboratory testing, but this practice is uncommon. Additionally, laboratory data were derived from DoD service members and may not be generalizable to a larger U.S. civilian population.

Given the findings of the current analysis, DoD healthcare providers, Combatant Commanders, and their command surgeons in areas of responsibility that include malaria-endemic regions should remain aware of the risks of 8-AQ hemolytic anemia in G6PD deficient service members. In addition, targeted health education and risk management instruction should be provided to G6PD deficient service members in order to mitigate adverse health outcomes. Furthermore, continued implementation of the DoD’s G6PD screening instruction is required to mitigate G6PD deficiency-associated adverse events.

 

Author affiliations: Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD (MAJ Jangwoo Lee); Defense Health Agency, Combat Support, Healthcare Operations, Public Health Division, Armed Forces Health Surveillance Branch, Navy Satellite (Beth T. Poitras)

Acknowledgments: The authors thank LTC Chad C. Black, LTC Mara Kreishman-Deitrick, COL James E. Moon, COL Viseth Ngauy, MAJ Brandon S. Pybus, and Angela D. Schlein for their support of this analysis and report.

Disclaimer: The views expressed in this report are those of the authors and do not necessarily reflect the official policy or position of the Armed Forces Health Surveillance Branch, the Defense Health Agency, the Department of the Army, the Department of the Navy, the Department of Defense, or the U.S. Government. Analytic support was provided by the Armed Forces Health Surveillance Branch of the Public Health Division at the Defense Health Agency. Authors are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.


REFERENCES

1. Richardson SR, O'Malley GF. (2019). Glucose 6 phosphate dehydrogenase (G6PD) deficiency. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470315/. Accessed 23 January 2019.

2. Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Eng J Med. 2018;378(1):60–71.

3. Department of Defense Instruction 6465.1. Hemoglobin S and erythrocyte glucose-6-phosphate dehydrogenase deficiency test program. 29 July 1981.

4. Webber BJ, Witkop CT. Screening for sickle-cell trait at accession to the United States military. Mil Med. 2014;179(11):1184–1189.

5. Department of Defense Instruction 6465.01. Erythrocyte glucose-6-phosphate dehydrogenase deficiency (G6PD) and sickle cell trait screening programs. 17 July 2015.

6. Department of Defense Instruction 6025.14. Active duty service members (ADSM) erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency and sickle cell trait (SCT) screening. 6 December 2018.

7. Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil Med. 2006;171(9):905–907.

8. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Eng J Med. 1979;300(18):1001–5.

9. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109:209–234.

10. Uddin DE, Dickson LG, Brodine CE. Glucose-6-phosphate dehydrogenase deficiency in military recruits. JAMA. 1974;227(12):1408–1409.

11. Fukuda M, Wojnarski M, Martin N, Zottig V, Waters NC. Editorial: Malaria in the Korean Peninsula: risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon. MSMR. 2018;25(11):2–3.

Results of G6PD deficiency laboratory testing among active duty DoD service members, 2004–2018

Classification of G6PD laboratory records among active duty DoD service members, by race/ethnicity and sex, 2004–2018

Classification of G6PD laboratory records among active duty DoD service members, by service, 2004–2018

You also may be interested in...

Acute Flaccid Myelitis Case Reporting

Infographic
1/29/2019
Acute Flaccid Myelitis Case Reporting

This case highlights important clinical characteristics of acute flaccid myelitis and emphasizes the importance of including AFM in the differential diagnosis when evaluating active duty service members and Military Health System beneficiaries presenting with paralysis.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Cardiovascular disease-related medical evacuations

Infographic
1/29/2019
Cardiovascular disease-related medical evacuations

This descriptive analysis summarizes the demographic characteristics, counts, rates and temporal trends for Cardiovascular disease-related medical evacuations from the CENTCOM area of responsibility. In addition, the percentage of those evacuated who had received pre-deployment diagnoses indicating cardiovascular risk is summarized. Responses to questions regarding health status and physician referrals on the DD2795 are also summarized.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Cardiovascular Disease-related Medical Evacuations, Active and Reserve Components, U.S. Armed Forces, 1 October 2001–31 December 2017

Article
1/1/2019
Cardiovascular Diagnoses

From 1 October 2001 through 31 December 2017, a total of 697 medical evacuations of service members from the U.S. Central Command (CENTCOM) area of responsibility were followed by at least one medical encounter in a fixed medical facility outside the operational theater with a diagnosis of a cardiovascular disease (CVD). The vast majority of those (n=660; 94.7%) evacuated were males. More than a third of CVD-related evacuations (n=278, 39.9%) occurred in service members 45 years of age or older; slightly more than half (n=369; 52.9%) occurred in reserve or guard members. The most common CVD risk factors which had been diagnosed among evacuated service members prior to their deployment were hypertension (n=236; 33.9%) and hyperlipidemia (n=241; 34.9%). Much lower percentages had been previously diagnosed with obesity (n=74, 10.6%) or diabetes (n=21, 3.0%). More than 1 in 4 service members with a CVD-related medical evacuation had been diagnosed with more than one risk factor (n=182, 26.1%). Both limitations to the data available and strategies to reduce CVD morbidity in theater are discussed.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Acute Flaccid Myelitis: Case Report

Article
1/1/2019
Acute Flaccid Myelitis

In August 2018, the U.S. Centers for Disease Control and Prevention (CDC) noted an increased number of reports of patients in the U.S. having symptoms clinically compatible with acute flaccid myelitis (AFM). AFM is characterized by rapid onset of flaccid weakness in one or more limbs and distinct abnormalities of the spinal cord gray matter on magnetic resonance imaging (MRI). Clinical and laboratory data suggest that AFM is associated with an antecedent viral infection. AFM may be difficult to differentiate from other causes of paralysis and, given that it is rare, has the potential to be overlooked. This case highlights important clinical characteristics of AFM and emphasizes the importance of including AFM in the differential diagnosis when evaluating active duty service members and Military Health System (MHS) beneficiaries presenting with paralysis.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Historical Perspective: Leptospirosis Outbreaks Affecting Military Forces

Article
1/1/2019
Acute Flaccid Myelitis

Leptospirosis is a widespread and highly prevalent bacterial zoonotic disease that is caused by pathogenic spirochetes of the genus Leptospira. It is transmitted to humans primarily through contact of abraded skin or mucous membranes with water or wet soil that has been contaminated with infected animal urine. Many wild and domestic animals are susceptible to infection by pathogenic Leptospira bacteria including rats, dogs, cattle, goats, sheep, and swine. Once chronically infected, a carrier animal can shed Leptospira bacteria in urine for long periods of time and Leptospira bacteria can survive in water or soil for weeks to months.higher among non-Hispanic white service members compared with those in other race/ethnicity groups. In both sexes, the annual rates of adrenal insufficiency and other disorders of adrenal gland increased slightly during the 16-year period.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Non-alcoholic Fatty Liver Disease (NAFLD), Active Component, U.S. Armed Forces, 2000–2017

Article
1/1/2019
Non-alcoholic fatty liver disease

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing’s syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Adrenal Gland Disorders, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018
Adrenal Glands

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing’s syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of the Metabolic Syndrome Using ICD-9 and ICD-10 Diagnostic Codes, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018
Metabolic Syndrome

This report uses ICD-9 and ICD-10 codes (277.7 and E88.81, respectively) for the metabolic syndrome (MetS) to summarize trends in the incidence and prevalence of this condition among active component members of the U.S. Armed Forces between 2002 and 2017. During this period, the crude overall incidence rate of MetS was 7.5 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, overall incidence rates were highest among Asian/Pacific Islanders, Air Force members, and warrant officers and were lowest among those of other/unknown race/ethnicity, Marine Corps members, and junior enlisted personnel and officers. During 2002–2017, the annual incidence rates of MetS peaked in 2009 at 11.6 cases per 100,000 p-yrs and decreased to 5.9 cases per 100,000 p-yrs in 2017. Annual prevalence rates of MetS increased steadily during the first 11 years of the surveillance period reaching a high of 38.9 per 100,000 active component service members in 2012, after which rates declined slightly to 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Thyroid Disorders, Active Component, U.S. Armed Forces, 2008–2017

Article
12/1/2018
Thyroid scan

This analysis describes the incidence and prevalence of five thyroid disorders (goiter, thyrotoxicosis, primary/not otherwise specified [NOS] hypothyroidism, thyroiditis, and other disorders of the thyroid) among active component service members between 2008 and 2017. During the 10-year surveillance period, the most common incident thyroid disorder among male and female service members was primary/NOS hypothyroidism and the least common were thyroiditis and other disorders of thyroid. Primary/NOS hypothyroidism was diagnosed among 8,641 females (incidence rate: 43.7 per 10,000 person-years [p-yrs]) and 11,656 males (incidence rate: 10.2 per 10,000 p-yrs). Overall incidence rates of all thyroid disorders were 3 to 5 times higher among females compared to males. Among both males and females, incidence of primary/NOS hypothyroidism was higher among non-Hispanic white service members compared with service members in other race/ethnicity groups. The incidence of most thyroid disorders remained stable or decreased during the surveillance period. Overall, the prevalence of most thyroid disorders increased during the first part of the surveillance period and then either decreased or leveled off.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Rabies

Infographic
11/20/2018
Rabies

Although Germany is rabies-free for terrestrial land mammals, rabies exposure remains a concern for U.S. military personnel assigned there because of personal and military travel and deployments to rabies endemic countries. Deployments have become much more variable both in location and duration. Deployments have increasingly focused on enhancing partnerships and peacekeeping.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Cold Weather Injuries

Infographic
11/20/2018
Cold Weather Injuries

This update summarizes the frequencies, incidence rates, and correlates of risk of cold injuries among members of both active and reserve components of the U.S. Armed Forces during the past 5 years.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Malaria

Infographic
11/20/2018
Malaria

This report describes a cluster of 11 soldiers with vivax malaria among U.S. military personnel who trained at Dagmar North training area, near the demilitarized zone (DMZ), in the Republic of Korea (ROK) in 2015.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

DoD Flu VE

Infographic
10/26/2018
DoD Flu VE

Each season, several entities within the(DoD) perform surveillance for influenza among beneficiaries and utilize these data to perform VE analyses to estimate how well the seasonal vaccine protects against medically-attended influenza.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health | Influenza Summary and Reports

Psychiatric Medical Evaluations

Infographic
10/26/2018
Psychiatric Medical Evaluations

This study evaluated incidence of pre-deployment family problem diagnoses and psychiatric medical evacuations among a population of active component service members without a history of previous mental health diagnoses, who deployed to the U.S. Central Command Area of Responsibility for the first time between 1 January 2002 and 31 December 2014.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Pelvic Inflammatory Disease

Infographic
10/26/2018
Pelvic Inflammatory Disease

The purpose of this study was to update previous MSMR analyses of the incidence of acute Pelvic inflammatory disease (PID) among U.S. active component women using a 21-year surveillance period from 1996 through 2016. A secondary objective was to report on the proportion of service women with previously diagnosed PID who were subsequently diagnosed with infertility or ectopic pregnancy.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health
<< < ... 6 7 8 9 10  ... > >> 
Showing results 121 - 135 Page 9 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.